분자영상 및 방사화학

본문글자크기
  • 2017년 06월호
    [Mol Pharm.] Artificial Chemical Reporter Targeting Strategy Using Bioorthogonal Click Reaction for Improving Active-Targeting Efficiency of Tumor.

    KIST/ 윤홍열, 신민이, 권익찬*, 김광명*

  • 출처
    Mol Pharm.
  • 등재일
    2017 May 1
  • 저널이슈번호
    14(5):1558-1570. doi: 10.1021/acs.molpharmaceut.6b01083. Epub 2017 Mar 15.
  • 내용

    바로가기  >

    Abstract

     

    Biological ligands such as aptamer, antibody, glucose, and peptide have been widely used to bind specific surface molecules or receptors in tumor cells or subcellular structures to improve tumor-targeting efficiency of nanoparticles. However, this active-targeting strategy has limitations for tumor targeting due to inter- and intraheterogeneity of tumors. In this study, we demonstrated an alternative active-targeting strategy using metabolic engineering and bioorthogonal click reaction to improve tumor-targeting efficiency of nanoparticles. We observed that azide-containing chemical reporters were successfully generated onto surface glycans of various tumor cells such as lung cancer (A549), brain cancer (U87), and breast cancer (BT-474, MDA-MB231, MCF-7) via metabolic engineering in vitro. In addition, we compared tumor targeting of artificial azide reporter with bicyclononyne (BCN)-conjugated glycol chitosan nanoparticles (BCN-CNPs) and integrin αvβ3 with cyclic RGD-conjugated CNPs (cRGD-CNPs) in vitro and in vivo. Fluorescence intensity of azide-reporter-targeted BCN-CNPs in tumor tissues was 1.6-fold higher and with a more uniform distribution compared to that of cRGD-CNPs. Moreover, even in the isolated heterogeneous U87 cells, BCN-CNPs could bind artificial azide reporters on tumor cells more uniformly (∼92.9%) compared to cRGD-CNPs. Therefore, the artificial azide-reporter-targeting strategy can be utilized for targeting heterogeneous tumor cells via bioorthogonal click reaction and may provide an alternative method of tumor targeting for further investigation in cancer therapy.

     

    Author information

    Yoon HY1, Shin ML1,2, Shim MK1,3, Lee S1, Na JH4, Koo H5, Lee H4, Kim JH3, Lee KY2, Kim K1,6, Kwon IC1,6.​

    1Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology , 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.2Department of Bioengineering, Hanyang University , 222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.3Department of Pharmacy, Graduate School, Kyung Hee University , 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.4College of Pharmacy, Graduate School of Pharmaceutical Science, Ewha Womans University , 52 Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea.5Department of Medical Lifescience, College of Medicine, The Catholic University of Korea , 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.6KU-KIST Graduate School of Converging Science and Technology, Korea University , 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea. 

  • 키워드
    active tumor targeting; bioorthogonal click reaction; heterogeneity; metabolic glycoengineering
  • 덧글달기
    덧글달기
       IP : 18.119.248.159

    등록